Lonza Group (LONN.SW) Stock Price

Lonza Group Price

SIX·CLOSED
579.60CHF+7.40 (+1.28 %)
Market closed

Revenue has compounded at 5.7% per year over the past 19 years to 6.53 B CHF. Earnings per share have grown at 7.0% per year over the last 19 years. Lonza Group's net margin stands at 14.5%, down from 54.4% several years earlier. Lonza Group currently offers a dividend yield of about 0.35%. The payout ratio is around 15% of earnings. The dividend has grown at 2.3% per year over the past 19 years. Analysts set a median price target of 678.30 CHF, implying 17.0% above the current price. Of 31 analysts, 26 rate the stock a buy — an overall Buy consensus. The stock trades about 24% above its 52-week low.

Lonza Group stock price

Volume
Ex-Dividend
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Lonza Group over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Lonza Group stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Lonza Group's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Lonza Group Stock Price History
DateLonza Group Price
8/10/2026579.60 CHF
8/7/2026572.20 CHF
8/6/2026566.60 CHF
8/5/2026561.40 CHF
8/4/2026560.40 CHF
8/3/2026560.20 CHF
7/31/2026562.20 CHF
7/30/2026577.20 CHF
7/29/2026574.80 CHF
7/28/2026558.60 CHF
7/27/2026559.40 CHF
7/24/2026548.00 CHF
7/23/2026543.20 CHF
7/22/2026536.40 CHF
7/21/2026564.00 CHF
7/20/2026565.00 CHF
7/17/2026573.20 CHF
7/16/2026575.20 CHF
7/15/2026581.40 CHF
7/14/2026582.40 CHF
7/13/2026584.40 CHF
7/10/2026586.00 CHF
7/9/2026582.60 CHF
7/8/2026573.80 CHF
7/7/2026574.40 CHF
7/6/2026580.40 CHF
7/3/2026567.20 CHF
7/2/2026564.60 CHF
7/1/2026562.60 CHF
6/30/2026545.80 CHF
6/29/2026539.60 CHF
6/26/2026534.60 CHF
6/25/2026537.20 CHF
6/24/2026528.40 CHF
6/23/2026515.20 CHF
6/22/2026500.40 CHF
6/19/2026496.30 CHF
6/18/2026488.10 CHF
6/17/2026495.40 CHF
6/16/2026501.20 CHF
6/15/2026496.10 CHF
6/12/2026499.30 CHF
6/11/2026499.20 CHF
6/10/2026497.70 CHF
6/9/2026495.30 CHF
6/8/2026480.90 CHF
6/5/2026494.20 CHF
6/4/2026489.30 CHF
6/3/2026486.70 CHF
6/2/2026504.00 CHF
6/1/2026497.20 CHF
5/29/2026507.20 CHF
5/28/2026493.40 CHF
5/27/2026498.60 CHF
5/26/2026491.50 CHF
5/22/2026497.10 CHF
5/21/2026497.10 CHF
5/20/2026489.20 CHF
5/19/2026488.00 CHF
5/18/2026468.30 CHF
5/15/2026469.40 CHF
5/13/2026474.20 CHF
5/12/2026478.10 CHF
5/11/2026481.80 CHF
5/8/2026483.00 CHF
5/7/2026486.20 CHF
5/6/2026493.60 CHF
5/5/2026490.20 CHF
5/4/2026479.20 CHF
4/30/2026479.20 CHF
4/29/2026474.00 CHF
4/28/2026482.70 CHF
4/27/2026488.60 CHF
4/24/2026479.80 CHF
4/23/2026499.10 CHF
4/22/2026508.20 CHF
4/21/2026511.00 CHF
4/20/2026526.00 CHF
4/17/2026543.40 CHF
4/16/2026531.60 CHF
4/15/2026533.80 CHF
4/14/2026529.00 CHF
4/13/2026517.00 CHF
4/10/2026515.00 CHF
4/9/2026506.20 CHF
4/8/2026508.60 CHF
4/7/2026510.60 CHF
4/2/2026514.00 CHF
3/27/2026494.20 CHF
3/26/2026492.61 CHF
3/25/2026486.94 CHF
3/24/2026477.07 CHF
3/23/2026468.38 CHF
3/20/2026473.30 CHF
3/19/2026481.50 CHF
3/17/2026482.30 CHF
3/16/2026482.30 CHF
3/13/2026484.50 CHF
3/12/2026484.50 CHF
3/11/2026496.50 CHF
3/10/2026496.50 CHF
3/9/2026498.50 CHF
3/6/2026508.53 CHF
3/5/2026525.60 CHF
2/27/2026536.50 CHF
2/26/2026531.19 CHF
2/25/2026526.60 CHF
2/23/2026520.60 CHF
2/20/2026536.40 CHF
2/19/2026533.00 CHF
2/18/2026533.40 CHF
2/17/2026527.20 CHF
2/16/2026524.00 CHF
2/13/2026521.00 CHF
2/12/2026506.80 CHF
2/11/2026516.60 CHF
2/10/2026516.60 CHF
2/9/2026517.20 CHF
2/6/2026513.18 CHF
2/5/2026526.00 CHF
2/4/2026526.07 CHF
2/3/2026529.60 CHF
2/2/2026525.00 CHF
1/30/2026534.00 CHF
1/29/2026531.46 CHF
1/28/2026558.40 CHF
1/27/2026554.20 CHF
1/26/2026555.40 CHF
1/23/2026555.20 CHF
1/22/2026557.40 CHF
1/21/2026543.60 CHF
1/20/2026540.60 CHF
1/19/2026559.20 CHF
1/16/2026564.20 CHF
1/14/2026562.42 CHF
1/13/2026565.10 CHF
1/12/2026565.71 CHF
1/9/2026552.76 CHF
1/8/2026550.63 CHF
1/7/2026546.38 CHF
1/6/2026538.44 CHF
1/5/2026535.15 CHF
1/2/2026537.90 CHF
12/31/2025537.98 CHF
12/30/2025535.80 CHF
12/29/2025534.00 CHF
12/24/2025532.74 CHF
12/23/2025531.60 CHF
12/22/2025530.70 CHF
12/19/2025530.20 CHF
12/18/2025523.80 CHF
12/17/2025523.80 CHF
12/16/2025520.17 CHF
12/15/2025517.63 CHF
12/12/2025516.60 CHF
12/11/2025528.02 CHF
12/10/2025537.04 CHF
12/9/2025541.64 CHF
12/6/2025547.50 CHF
12/4/2025549.89 CHF
12/2/2025552.39 CHF
12/1/2025557.12 CHF
11/28/2025547.70 CHF
11/27/2025540.80 CHF
11/25/2025530.80 CHF
11/24/2025535.26 CHF
11/21/2025533.66 CHF
11/20/2025530.00 CHF
11/19/2025527.56 CHF
11/18/2025529.13 CHF
11/17/2025540.35 CHF
11/15/2025543.55 CHF
11/13/2025554.60 CHF
11/12/2025552.80 CHF
11/10/2025534.20 CHF
11/7/2025528.76 CHF
11/6/2025532.88 CHF
11/5/2025533.00 CHF
11/4/2025533.20 CHF
11/3/2025546.68 CHF
10/31/2025554.47 CHF
10/30/2025556.00 CHF
10/29/2025569.60 CHF
10/28/2025570.40 CHF
10/27/2025585.00 CHF
10/25/2025585.69 CHF
10/23/2025577.67 CHF
10/22/2025559.74 CHF
10/21/2025554.28 CHF
10/20/2025553.10 CHF
10/17/2025550.63 CHF
10/16/2025546.81 CHF
10/15/2025531.25 CHF
10/14/2025529.40 CHF
10/13/2025527.40 CHF
10/10/2025544.20 CHF
10/9/2025544.80 CHF
10/8/2025540.20 CHF
10/7/2025540.20 CHF
10/6/2025553.60 CHF
10/3/2025542.40 CHF
10/2/2025534.60 CHF
10/1/2025527.20 CHF
9/29/2025519.80 CHF
9/26/2025522.20 CHF
9/25/2025518.00 CHF
9/24/2025525.80 CHF
9/23/2025536.20 CHF
9/22/2025542.53 CHF
9/19/2025541.30 CHF
9/18/2025544.01 CHF
9/17/2025546.86 CHF
9/16/2025548.00 CHF
9/15/2025547.17 CHF
9/12/2025549.34 CHF
9/11/2025558.70 CHF
9/10/2025560.77 CHF
9/9/2025568.44 CHF
9/8/2025570.43 CHF
9/5/2025577.85 CHF
9/4/2025582.14 CHF
9/3/2025570.60 CHF
9/2/2025569.80 CHF
9/1/2025569.14 CHF
8/29/2025569.22 CHF
8/28/2025569.61 CHF
8/27/2025574.39 CHF
8/26/2025575.21 CHF
8/25/2025569.74 CHF
8/22/2025569.35 CHF
8/21/2025570.56 CHF
8/20/2025572.12 CHF
8/19/2025557.54 CHF
8/18/2025554.40 CHF
8/15/2025554.75 CHF
8/14/2025550.60 CHF
8/13/2025546.00 CHF
8/12/2025545.88 CHF
8/11/2025544.60 CHF
Access this data via the Eulerpool API
Get Free API Key

Lonza Group Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
6.72 B CHF
880.00 M CHF
654.00 M CHF
Jan 1, 2024
6.57 B CHF
964.00 M CHF
636.00 M CHF
Jan 1, 2025
6.53 B CHF
1.38 B CHF
949.00 M CHF
Jan 1, 2026 (e)
7.12 B CHF
1.24 B CHF
1.29 B CHF
Jan 1, 2027 (e)
7.95 B CHF
1.38 B CHF
1.54 B CHF
Jan 1, 2028 (e)
8.88 B CHF
1.54 B CHF
1.74 B CHF
Jan 1, 2029 (e)
10.02 B CHF
1.74 B CHF
2.10 B CHF
Jan 1, 2030 (e)
11.14 B CHF
1.93 B CHF
2.34 B CHF

Lonza Group Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 10, 2026, 7:17 PM
 
REVENUEB CHF
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEB CHF
EBITB CHF
EBIT MARGIN%
NET INCOMEB CHF
NET INCOME GROWTH%
DIV.CHF
DIV. GROWTH%
SHARESM
201520162017201820192020202120222023202420252026e2027e2028e2029e2030e
3.804.134.555.544.214.515.416.226.726.576.537.127.958.8810.0211.14
4.488.6510.0721.86-24.097.1519.9915.057.94-2.13-0.659.0611.6411.6812.8611.15
30.5035.2139.0939.3242.2637.8439.0139.1829.0032.8635.3535.3535.3535.3535.3535.35
1.161.461.782.181.781.712.112.441.952.162.312.522.813.143.543.94
0.500.620.820.910.920.940.851.540.880.961.381.241.381.541.741.93
13.0914.9318.0516.3521.8220.7915.7324.7613.1014.6621.1617.3417.3217.3617.3617.36
0.280.300.730.560.650.872.941.220.650.640.951.291.541.742.102.34
16.888.66141.20-23.0015.3834.73238.78-58.73-46.17-2.7549.2135.7219.4113.2020.7911.36
2.502.502.752.752.751.381.501.501.752.002.005.006.007.20––
16.28–10.00––-49.828.70–16.6714.29–150.0020.0020.00––
52.7852.8768.4674.6174.6074.8174.4874.3172.7074.1270.1870.1870.1870.1870.1870.18
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Lonza Group generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Lonza Group retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Lonza Group's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Lonza Group has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Lonza Group's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Lonza Group stock margins

The Lonza Group margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Lonza Group. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Lonza Group.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
39.01 %
15.73 %
54.43 %
Jan 1, 2022
39.18 %
24.76 %
19.52 %
Jan 1, 2023
29.00 %
13.10 %
9.74 %
Jan 1, 2024
32.86 %
14.66 %
9.67 %
Jan 1, 2025
35.35 %
21.16 %
14.53 %
Jan 1, 2026 (e)
35.35 %
17.34 %
18.09 %
Jan 1, 2027 (e)
35.35 %
17.33 %
19.34 %
Jan 1, 2028 (e)
35.35 %
17.36 %
19.61 %

Lonza Group Stock Revenue, EBIT, Earnings per Share

The Lonza Group earnings per share therefore indicates how much revenue Lonza Group has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
72.62 CHF
11.43 CHF
39.52 CHF
Jan 1, 2022
83.75 CHF
20.74 CHF
16.35 CHF
Jan 1, 2023
92.39 CHF
12.10 CHF
9.00 CHF
Jan 1, 2024
88.69 CHF
13.01 CHF
8.58 CHF
Jan 1, 2025
93.06 CHF
19.69 CHF
13.52 CHF
Jan 1, 2026 (e)
101.41 CHF
17.60 CHF
18.35 CHF
Jan 1, 2027 (e)
113.21 CHF
19.63 CHF
21.90 CHF
Jan 1, 2028 (e)
126.44 CHF
21.98 CHF
24.79 CHF

Lonza Group business model & stock analysis

The Lonza Group AG is a global company based in Basel, Switzerland. It was founded in 1897 and has since had a long history of operational excellence and innovation. Lonza is a leading provider of customized chemical and biotechnological solutions and services for customers in the health, agrochemical, life science, and other sectors. Lonza's business model is based on providing customized, customer-oriented solutions for complex chemical and biological challenges. The company focuses on three main divisions: Pharma & Biotech, Consumer Health, and Specialty Ingredients. Within these divisions, Lonza offers a variety of products, services, and solutions tailored to meet the specific needs of its customers. In the Pharma & Biotech division, Lonza offers a wide range of products and services for the pharmaceutical and biotechnology industries. The company is a global leader in active ingredients for the pharmaceutical industry and also provides custom process development and manufacturing services for biopharmaceuticals and small molecules. In the Consumer Health division, Lonza develops and produces a variety of dietary supplements, cosmetic products, and household products for its customers. The company is a recognized expert in the formulation and production of high-quality dietary supplements and has also established a strong position in the production of natural cosmetic products in recent years. Lonza's Specialty Ingredients division offers a wide range of chemical and biotechnological products and services for the life science and specialty chemical industries. This includes products and services such as microbial control, material protection, custom development services, and others. Lonza is a leading manufacturer and supplier of dietary supplements, pharmaceutical active ingredients, agrochemicals, cosmetic ingredients, and other chemical and biotechnological products. The company has extensive expertise in process development and optimization, as well as in the manufacturing of products for various industries. One of Lonza's key products is the active ingredient Mipomersen, which is used in the treatment of familial hypercholesterolemia. Lonza is also a major provider of dietary supplements, particularly vitamins, minerals, omega-3 fatty acids, and other nutrients that can promote and support human health. Another important product of Lonza is the biosimilar component recombinant human insulin, which is used in the treatment of diabetes. Overall, Lonza is an innovative and leading company in the field of chemistry and biotechnology. With a strong focus on customer-oriented solutions and a broad portfolio of products and services, the company is well positioned to meet the growing demand for chemical and biological solutions in various industries.

Lonza Group SWOT Analysis

Strengths

Lonza Group AG benefits from several strengths that contribute to its success:

  • Diverse Product Portfolio: Lonza offers a wide range of products across different industries, including pharmaceuticals, specialty chemicals, and biotechnology, providing stability and growth opportunities.
  • Strong R&D Capabilities: Lonza's focus on research and development enables continuous innovation, enhancing its product offerings and supporting its competitiveness in the market.
  • Global Presence: Lonza has a widespread global presence, with operations in multiple countries, allowing it to serve diverse markets and access a larger customer base.
  • Strong Financial Performance: Lonza has demonstrated strong financial performance, including consistent revenue growth and profitability, indicating its operational excellence and financial stability.

Weaknesses

Despite its strengths, Lonza Group AG also faces certain weaknesses that might hinder its growth and performance:

  • Reliance on Key Customers: Lonza depends on a few key customers for a significant portion of its revenue, which exposes the company to potential risks if there are changes in these customer relationships.
  • Regulatory Compliance Challenges: As a company operating in highly regulated industries such as pharmaceuticals and biotechnology, Lonza faces compliance challenges with respect to evolving regulations, which may increase costs and affect its operations.
  • Complex Supply Chain: Lonza's diverse product portfolio and global operations make its supply chain complex, which can lead to logistical challenges and increase the risk of disruptions.

Opportunities

Lonza Group AG can leverage several opportunities to fuel its growth and expand its market presence:

  • Increasing Demand for Biopharmaceuticals: The growing demand for biopharmaceuticals presents a significant opportunity for Lonza as it has expertise in this field, allowing the company to capture a larger market share and generate higher revenues.
  • Expansion in Emerging Markets: Lonza can explore expansion opportunities in emerging markets, where the demand for specialty chemicals and biotechnology products is rising rapidly, offering access to new customer segments and revenue sources.
  • Strategic Collaborations and Partnerships: Collaborations with key players in the industry, as well as academic institutions and research organizations, can enable Lonza to strengthen its research capabilities and develop innovative solutions to address market needs.

Threats

Lonza Group AG needs to be mindful of certain threats that could impact its business operations:

  • Intense Competition: Lonza operates in highly competitive industries where numerous players strive to capture market share. Increased competition might lead to price pressures, reduced margins, and potential loss of customers.
  • Fluctuating Raw Material Prices: Lonza's business is influenced by fluctuations in raw material prices. Price volatility can impact the company's profitability if it is unable to pass on the cost increases to customers.
  • Geopolitical and Economic Uncertainties: Global political and economic uncertainties, such as trade disputes, regulatory changes, and economic downturns in key markets, can hinder Lonza's growth prospects and disrupt its international operations.

Lonza Group Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Lonza Group historical P/E ratio, EBIT multiple, and P/S ratio

Lonza Group annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Lonza Group shares outstanding

The number of shares of Lonza Group was 70.18 M in 2025. This indicates how many shares Lonza Group is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
74.48 M Stocks
Jan 1, 2022
74.31 M Stocks
Jan 1, 2023
72.70 M Stocks
Jan 1, 2024
74.12 M Stocks
Jan 1, 2025
70.18 M Stocks
Jan 1, 2026 (e)
70.18 M Stocks
Jan 1, 2027 (e)
70.18 M Stocks
Jan 1, 2028 (e)
70.18 M Stocks

Lonza Group stock splits

In Lonza Group's history, there have been no stock splits.

Lonza Group Dividend History

27 years of dividend payments

YearAnnual DividendYoY ChangePayments
20265.00CHFYTD—2×
May 12, 20262.50CHF↑ 25.0%1/2
May 13, 20262.50CHF 0.0%2/2
20252.00CHF 0.0%1×
May 13, 20252.00CHF 0.0%1/1
20242.00CHF↑ 14.3%1×
20231.75CHF↑ 16.7%1×
20221.50CHF 0.0%1×
20211.50CHF↑ 9.1%1×
20201.38CHF↓ 50.0%1×
20192.75CHF 0.0%1×
20182.75CHF 0.0%1×
20172.75CHF↑ 10.0%1×

Lonza Group dividend history and estimates

In 2025, Lonza Group paid a dividend amounting to 2.00 CHF. Dividend means that Lonza Group distributes a portion of its profits to its owners.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Dividend
Details
Date
Dividend
Dividend (Estimate)
Jan 1, 2021
1.50 CHF
0.00 CHF
Jan 1, 2022
1.50 CHF
0.00 CHF
Jan 1, 2023
1.75 CHF
0.00 CHF
Jan 1, 2024
2.00 CHF
0.00 CHF
Jan 1, 2025
2.00 CHF
0.00 CHF
Jan 1, 2026
5.00 CHF
0.00 CHF
Jan 1, 2027 (e)
0.00 CHF
6.00 CHF
Jan 1, 2028 (e)
0.00 CHF
7.20 CHF

Lonza Group dividend payout ratio

In 2025, Lonza Group had a payout ratio of 14.79%. The payout ratio indicates the percentage of the company's profits that Lonza Group distributes as dividends.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2021
3.80 %
Jan 1, 2022
9.17 %
Jan 1, 2023
19.45 %
Jan 1, 2024
23.31 %
Jan 1, 2025
14.79 %
Jan 1, 2026 (e)
27.25 %
Jan 1, 2027 (e)
27.40 %
Jan 1, 2028 (e)
29.04 %

Current Lonza Group forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.75 %
Buy
83.87 % (26)
Hold
16.13 % (5)
Sell
0.00 % (0)
12M Price Target
678.30
Last Price
572.20
Currency
CHF
12M Return Potential
18.54 %
LTM Return
0 %

Lonza Group Analyst Rating Actions

DateFirmActionRatingReliability
2/22/2021
JP Morgan
JP Morgan
UpgradeNeutralOverweight80
11/10/2020
KeyBanc
KeyBanc
MaintainedSector WeightEqual Weight49
11/10/2020
Keybanc
Keybanc
MaintainedSector WeightEqual Weight49

Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.

Lonza Group Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
1/23/20246.55CHF-3.42 BCHF-2023 Q4
1/24/20237.81CHF-3.32 BCHF-2022 Q4
7/22/20227.74CHF-3.02 BCHF-2022 Q2
1/26/20226.73CHF-2.68 BCHF-2021 Q4
7/23/20216.48CHF-2.54 BCHF-2021 Q2
1/27/20216.19CHF-2.93 BCHF-2020 Q4
7/24/20206.21CHF-3.10 BCHF-2020 Q2
1/21/20205.94CHF-2.96 BCHF-2019 Q4
7/24/20196.35CHF-3.01 BCHF-2019 Q2
1/30/20195.98CHF-2.93 BCHF-2018 Q4

EESG©

Eulerpool ESG Scorecard© for the Lonza Group stock

96/100
99
Environment
99
Social
91
Governance
E

Environment

20
Scope 1 - Direct Emissions319,000
Scope 2 - Indirect emissions from purchased energy218,000
Scope 3 - Indirect emissions within the value chain1,878,000
Total CO₂ emissions537,000
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees37
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Lonza Group shareholder structure

% Name
9.84786%
BlackRock Investment Management (UK) Ltd.
BlackRock Investment Management (UK) Ltd.
6.24464%
UBS Asset Management (Switzerland)
UBS Asset Management (Switzerland)
3.21756%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
1.82197%
BlackRock Institutional Trust Company, N.A.
BlackRock Institutional Trust Company, N.A.
1.76900%
Zürcher Kantonalbank (Asset Management)
Zürcher Kantonalbank (Asset Management)
1.36973%
Invesco Advisers, Inc.
Invesco Advisers, Inc.
...

Lonza Group Beneficial Ownership Filings (SEC 13D/G)

Free Float
99.9%
Float Shares
-
Shares Outstanding
-

Lonza Group Executives and Management Board

21 members · avg. age 59 · 24 % women

WW

Dr. Wolfgang Wienand (53)

Chief Executive Officer, Member of the Executive Committee

6.42 M CHF

Management

JS

Mr. Juergen Steinemann (67)

Independent Non-Executive Vice Chairman of the Board

255,773.00 CHF
PD

Mr. Philippe Deecke (53)

Chief Financial Officer, Member of the Executive Committee

–
NB

Ms. Nicoleta Baumgartner (54)

Chief Human Resources Officer, Member of the Executive Committee

–
GB

Mr. Gordon Bates (60)

Head of Integrated Biologics, Member of the Executive Committee

–
JB

Mr. Jason Berndt

Head of Group Operations and Member of the Executive Committee

–
AB

Mr. Andreas Bohrer

Chief Legal & Corporate Affairs Officer and Member of the Executive Committee

–

Board of Directors

JH

Mr. Jean Marc Huet (56)

Independent Non-Executive Chairman of the Board

547,742.00 CHF
CM

Mr. Christoph Maeder (65)

Lead Independent Director

334,839.00 CHF
AK

Ms. Angelica Kohlmann (65)

Independent Member of the Board

334,469.00 CHF
BR

Ms. Barbara Richmond (64)

Independent Member of the Board

316,488.00 CHF
PN

Prof. Roger Nitsch (64)

Independent Member of the Board

268,245.00 CHF
MH

Ms. Marion Helmes (60)

Independent Member of the Board

255,773.00 CHF

Frequently asked questions about Lonza Group

The business model of Lonza Group AG is centered around providing customized and integrated solutions for the life sciences and specialty ingredients markets. Lonza operates through two main segments: Pharma & Biotech and Specialty Ingredients. In the Pharma & Biotech segment, Lonza offers contract development and manufacturing services for the pharmaceutical and biotechnology industries. This includes the development and production of active pharmaceutical ingredients and drug product manufacturing. The Specialty Ingredients segment focuses on providing high-quality ingredients and formulation solutions for various industries, including personal care, consumer health, and agro ingredients. Lonza Group AG aims to support its customers by delivering innovative and sustainable solutions in both segments.

Lonza Group AG is primarily active in the life sciences and specialty ingredients industries.

The main competitors of Lonza Group AG in the market include companies such as Merck KGaA, Thermo Fisher Scientific Inc., and Lonza's own subsidiary, Capsugel.

Lonza Group AG, a leading Swiss biotechnology and pharmaceutical company, has a rich history and background. Established in 1897 in Basel, Switzerland, Lonza has grown into a global powerhouse over the years. Originally a textile chemicals manufacturing firm, Lonza shifted its focus to life sciences in the early 20th century. The company specializes in providing advanced solutions and technologies for various industries, including healthcare, pharmaceuticals, and nutrition. Lonza Group AG is renowned for its expertise in cell and gene therapy, microbial control, and drug discovery. With a strong commitment to innovation, sustainability, and quality, Lonza continues to shape the future of healthcare and life sciences globally.

Lonza Group AG has achieved several significant milestones throughout its history. Some notable achievements include its establishment in 1897, its listing on the SIX Swiss Exchange in 1986, and its expansion into a global leader in life science and specialty ingredients. Lonza has gained recognition for its expertise in biopharmaceutical contract manufacturing and has successfully developed new innovative products and services. The company has also made strides in sustainability efforts, aiming to reduce its carbon emissions and environmental impact. Lonza continues to demonstrate its commitment to excellence and remains a leading player in the life science industry.

Lonza Group AG is primarily present in various countries and regions worldwide. The company has a global footprint and operates in several key markets, including but not limited to Switzerland, United States, Germany, Singapore, China, and United Kingdom. With its extensive international presence, Lonza Group AG leverages its expertise and capabilities to serve customers and deliver innovative solutions in the life sciences and specialty ingredients sectors. As a multinational corporation, Lonza Group AG's global reach allows it to capitalize on opportunities and meet the diverse needs of customers across different geographies.

Lonza Group AG is a prominent company that stands for strong values and a distinguished corporate philosophy. With a focus on delivering innovative solutions, Lonza prioritizes excellence, quality, and integrity in all its endeavors. The company strives to foster long-term partnerships while promoting sustainability and enhancing human health. By combining expertise in science and technology, Lonza creates value and supports customers in various industries worldwide. Moreover, as a responsible corporate entity, Lonza Group AG maintains a commitment to ethical practices, social responsibility, and environmental stewardship, ensuring that its operations align with the highest standards of corporate governance.

Analysts currently set an average price target of 680.23 CHF for the Lonza Group stock (median: 678.30 CHF), implying +18.9 % versus the latest price. The consensus is based on 31 analyst ratings.

Lonza Group Analyst Price Targets 2026

31 analysts currently rate the Lonza Group stock: 26 recommend buying, 5 holding and 0 selling. For 2026, analysts expect Lonza Group to generate revenue of 7.12 B CHF and earnings per share of 18.36 CHF.

Lonza Group Analyst Price Targets 2026

Converted at the current exchange rate, the Lonza Group share trades at 620.44 EUR (579.60 CHF).

The Lonza Group share (LONN.SW) is listed on 8 stock exchanges, including: Frankfurt (LO3.F), München (LO3.MU), Düsseldorf (LO3.DU), Hamburg (LO3.HM), London (0QNO.L), London (0QNO.L), SIX (Zürich) (LONN.SW).

The Lonza Group AG is a leading company in the pharmaceutical, biotech, and specialty chemical industries. Its business model is based on the manufacturing and provision of solutions and services for its customers worldwide. The company is divided into three business segments: Pharma, Biotech, and Specialty Ingredients. Each segment serves different industries and customers and offers a wide range of products and services. The Pharma business segment offers a variety of products and services for pharmaceutical companies, including active ingredients, formulations, dosage forms, manufacturing processes, and biologics. Lonza's products and services are used by customers worldwide for the development and manufacturing of pharmaceuticals. The Biotech business segment offers solutions and services for the biotechnology industry, such as biotechnological active ingredients, cell therapies, and gene therapies. Lonza's customers use these products and services for the development of innovative therapies and medicines. The Specialty Ingredients business segment offers a comprehensive range of specialty chemicals and engineering services, including food additives, fragrances, flavors, and solutions for the aviation and electronics industries. Lonza's customers use these products and services to improve their products and provide their customers with unique and innovative solutions. Lonza also provides its customers with innovative technologies and capabilities to optimize their development and manufacturing processes. The company strives to provide its customers with comprehensive support to help them solve complex challenges in their industries. In addition to its products and services, Lonza works closely with its customers to offer customized solutions. The company ensures that its products and services meet the requirements of its customers and are continuously improved and developed. Lonza's business model is also based on sustainability. The company is committed to acting responsibly and sustainably to have a positive impact on the environment and society. This is reflected in how the company develops its product range and engages with the communities in which it operates. In summary, Lonza's business model is focused on the manufacturing and sale of products and services that meet the requirements of its customers. The company relies on innovative technologies and is committed to providing its customers with comprehensive support. Lonza also strives to promote and implement responsibility and sustainability in all aspects of its business model.

The expected revenue of Lonza Group is 7.12 B CHF. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Lonza Group is 1.29 B CHF. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Lonza Group is currently 31.57. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Lonza Group stock.

The price-to-sales ratio (P/S) of Lonza Group is currently 5.71. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Lonza Group stock.

The Eulerpool Quality Score for Lonza Group is 6/10.

The ISIN of Lonza Group is CH0013841017. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Lonza Group is 928619. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Lonza Group is LONN.SW. The ticker symbol is used to trade Lonza Group shares on the stock exchange.

Over the past 12 months, Lonza Group paid a dividend of 2.00 CHF . This corresponds to a dividend yield of about 0.35 %. For the coming 12 months, Lonza Group is expected to pay a dividend of 6.00 CHF.

The current dividend yield of Lonza Group is 0.35 %.

Lonza Group pays a dividend, distributed in the months of , , , .

Lonza Group paid dividends every year for the past 26 years.

For the upcoming 12 months, dividends amounting to 6.00 CHF are expected. This corresponds to a dividend yield of 1.05 %.

Lonza Group is assigned to the 'Health' sector.

To receive the latest dividend of Lonza Group from amounting to 2.5 CHF, you needed to have the stock in your portfolio before the ex-date on .

The last dividend was paid out on .

In the year 2025, Lonza Group distributed 2 CHF as dividends.

The dividends of Lonza Group are distributed in CHF.

All fundamentals and in-depth analysis of Lonza Group

Our stock analysis for Lonza Group stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Lonza Group. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Lonza Group Stock
Lonza Group Revenue→
Lonza Group Stock
Lonza Group Net Income→
Lonza Group Stock
Lonza Group P/E→
Lonza Group Stock
Lonza Group P/S→
Lonza Group Stock
Lonza Group EBIT→
Lonza Group Stock
Lonza Group Dividend→
Lonza Group Stock
Lonza Group Directors Dealings→
Lonza Group Stock
Lonza Group Stocks→
Lonza Group Stock
Lonza Group Market capitalization→
Lonza Group Stock
Lonza Group Debt→
Lonza Group Stock
Lonza Group Liabilities→
Lonza Group Stock
Lonza Group Equity→
Lonza Group Stock
Lonza Group AAQS→
Lonza Group Stock
Lonza Group Employees→
Lonza Group Stock
Lonza Group ROE→
Lonza Group Stock
Lonza Group ROA→
Lonza Group Stock
Lonza Group ROCE→
Lonza Group Stock
Lonza Group News→
Lonza Group Stock
Lonza Group Analyst Price Targets→

Health Stocks

Looks Health ServicesLongportLotus Eye Hospital and InstituteLongevity Health HoldingsLotus Pharmaceutical CoLongeveronLotus PharmaceuticalsLongduoduo CoLTR PharmaLombard MedicalLucid DiagnosticsLogicMark Inc (Pre-Merger)All Stocks A–Z →